• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Monogram Orthopaedics Reports First Quarter 2024 Financial Results

    5/14/24 9:17:00 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care
    Get the next $MGRM alert in real time by email

    Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half of 2024

    Engaged Contract Research Organization to Oversee mBôs Robot Clinical Trial Activities Outside the U.S.

    Management to Host Business Update Conference Call on Wednesday, May 22 at 4:30 p.m. Eastern Time

    AUSTIN, TX / ACCESSWIRE / May 14, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2024.

    First Quarter 2024 and Subsequent Operational Highlights

    • Received feedback from the U.S. Food and Drug Administration (the "FDA") for the Company's verification test protocols and proposed clinical trial protocol on an outside the U.S. (OUS) target population.
    • The Company anticipates that Verification and Validation testing will be largely complete in Q2 of 2024 and anticipates a 510(k) submission to follow in the second half of 2024.
    • Introduced mVision technology, a novel approach to registration and tracking that the company is now working on as a standalone product or for integration into the mBôs surgical robotic system in the future.
    • Presented a product discussion featuring Monogram's mBôs and mVision technologies with a surgeon panel.
    • Presented at the Canaccord Genuity 2024 Musculoskeletal Conference

    Management Commentary

    "In the first quarter, we took the initiative to accelerate our commercial timeline by making key modifications to our strategy," said Ben Sexson, Chief Executive Officer of Monogram. "Our team has worked tirelessly to advance Monogram toward the critical milestone of a 510(k) submission. The inherent value of our mBôs surgical robot, our mVision technology, and our underlying IP is gaining increasing recognition within both the orthopedic and robotics industries.

    "Our communications with the FDA related to our mBôs™ TKA System verification test plan and OUS clinical trial protocol have been productive. Based on the FDA's feedback, we believe our proposed testing plan is sufficient for evaluating the safety and effectiveness of our robotic system, supporting a strong 510(k) submission with the goal of ultimately obtaining FDA clearance. Our team has been active with the rigorous internal and external testing that encompasses the Verification and Validation phase, which we expect to be largely complete by the end of Q2 2024. We look forward to providing updates in the months to come as we continue to execute our commercialization strategy," concluded Sexson.

    Upcoming 2024 Milestones

    • Largely complete mBôs system verification and validation - H1 2024
    • Submit 510(k) application to FDA - H2 2024
    • Progress towards OUS live-patient surgery trials
    • Expanded international relationships

    First Quarter 2024 Financial Results

    Research and development expenses for the first quarter ended March 31, 2024, were $2.4 million, compared to $1.9 million the prior-year quarter. The R&D increase was primarily due to the Company moving into the verification and validation phase of its robot prototype, which is expected to be largely complete the first half of 2024, as well as the introduction of mVision technology in the first quarter.

    General & administrative expenses for the first quarter ended March 31, 2024, were $1.1 million compared to $0.8 million in the prior-year quarter. The increase was primarily due to increases in consulting fees, insurance and regulatory compliance and professional fees.

    Net loss was $3.5 million for the first quarter ended March 31, 2024, an improvement compared to a net loss of $3.9 million for the prior-year quarter.

    Cash and cash equivalents totaled $10.1 million as of March 31, 2024, compared to $13.6 million as of December 31, 2023.

    First Quarter 2024 Business Update Conference Call

    Monogram Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape will host the conference call, followed by a question-and-answer period.

    To access the call, please use the following information:

    Date: Wednesday, May 22, 2024
    Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
    Registration Link: https://streamyard.com/watch/wvMTc4vvHEgn

    About Monogram Orthopaedics

    Monogram Orthopaedics (NASDAQ:MGRM) is working to develop a product solution architecture with the long-term goal of enabling patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The Company has a robotic system that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. The Company has not yet made 510(k) premarket notification submissions or obtained 510(k) clearances for its robotic products. FDA approval is required to market these products, and the Company has not obtained FDA approval for any of its robotic products, and it cannot estimate the timing or assure the ability, to obtain such clearances.

    Monogram Orthopaedics is working to advance the way orthopedic surgery is done. Our system is being developed to combine personalized knee implants with precision robotic surgical systems to give patients a better-fitting knee replacement with minimally invasive surgery. One hundred thousand knee replacements failing each year in a $19.4B market represents an enormous opportunity for us.

    To learn more, visit www.monogramorthopedics.com.

    Forward-Looking Statements

    This press release may include "forward-looking statements.'' To the extent that the information presented in this presentation discusses financial projections, information, or expectations about the Company's business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and the Company does not undertake any duty to update any forward-looking statements except as may be required by law.

    Investor Relations

    Chris Tyson
    Executive Vice President
    MZ North America
    Direct: 949-491-8235
    [email protected]

    MONOGRAM ORTHOPAEDICS INC.
    CONDENSED BALANCE SHEETS


    March 31, December 31,

    2024 2023

    (unaudited)
    Assets


    Current assets:


    Cash and cash equivalents
    $10,077,573 $13,589,028
    Account receivable
    - 364,999
    Prepaid expenses and other current assets
    629,751 664,262
    Total current assets
    10,707,324 14,618,289
    Equipment, net of accumulated depreciation
    903,011 945,020
    Intangible assets, net
    496,250 548,750
    Operating lease right-of-use assets
    435,116 466,949
    Total assets
    $12,541,701 $16,579,008
    Liabilities and Stockholders' Equity
    Current liabilities:
    Accounts payable
    $1,321,313 $2,462,268
    Accrued liabilities
    531,239 227,684
    Operating lease liabilities, current
    131,081 128,266
    Total current liabilities
    1,983,633 2,818,218
    Operating lease liabilities, non-current
    330,561 363,724
    Total liabilities
    2,314,194 3,181,942
    Commitments and contingencies
    - -
    Stockholders' equity:
    Common stock, $.001 par value; 90,000,000 shares authorized, 31,633,995 and 31,338,391 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
    31,634 31,338
    Additional paid-in capital
    65,211,241 64,874,392
    Accumulated deficit
    (55,015,368) (51,508,664)
    Total stockholders' equity
    10,227,507 13,397,066
    Total liabilities and stockholders' equity
    $12,541,701 $16,579,008

    MONOGRAM ORTHOPAEDICS INC.
    CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)


    Three months ended

    March 31,

    2024 2023
    Product revenue
    $- $-
    Cost of goods sold
    - -
    Gross profit
    - -
    Operating expenses:
    Research and development
    2,406,754 1,939,551
    Marketing and advertising
    119,694 1,132,625
    General and administrative
    1,083,711 822,889
    Total operating expenses
    3,610,159 3,895,065
    Loss from operations
    (3,610,159) (3,895,065)
    Other income:
    Change in fair value of warrant liability
    - 2,523
    Interest income and other, net
    103,455 34,820
    Total other income
    103,455 37,343
    Net loss before taxes
    (3,506,704) (3,857,722)
    Income taxes
    - -
    Net loss
    $(3,506,704) $(3,857,722)
    Basic and diluted loss per common share
    $(0.11) $(0.40)
    Weighted-average number of basic and diluted shares outstanding
    31,535,795 9,673,870

    MONOGRAM ORTHOPAEDICS INC.
    CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)


    Three months ended

    March 31,

    2024 2023
    Operating activities:


    Net loss
    $(3,506,704) $(3,857,722)
    Adjustments to reconcile net loss to net cash used in operating activities:
    Stock-based compensation
    294,899 368,140
    Other expenses settled with stock issuances
    37,500 -
    Loss from change in fair value of common stock make-whole obligation
    45,252 -
    Depreciation and amortization
    105,898 102,503
    Change in fair value of warrant liability
    - (2,523)
    Changes in non-cash working capital balances:
    Account receivable
    364,999 -
    Other current assets
    (111,445) 231,518
    Accounts payable
    (1,140,955) 516,762
    Accrued liabilities
    258,303 (243,501)
    Operating lease assets and liabilities, net
    1,485 2,446
    Cash used in operating activities
    (3,650,768) (2,882,377)
    Investing activities:
    Purchases of equipment
    (11,389) (14,792)
    Cash used in investing activities
    (11,389) (14,792)
    Financing activities:
    Proceeds from issuances of Common Stock, net of cash costs
    150,702 -
    Proceeds from issuances of Series C Preferred Stock, net
    - 147,042
    Cash provided by financing activities
    150,702 147,042
    Decrease in cash and cash equivalents during the period
    (3,511,455) (2,750,127)
    Cash and cash equivalents, beginning of the period
    13,589,028 10,468,645
    Cash and cash equivalents, end of the period
    $10,077,573 $7,718,518

    Cash paid for interest
    $- $-
    Cash paid for income taxes
    $- $-
    Noncash investing and financing activities:
    Amortization of deferred issuance costs of Common Stock Purchase Agreement
    $145,956 $-
    Cashless exercise of warrant
    $246 $-

    SOURCE: MONOGRAM ORTHOPAEDICS INC



    View the original press release on accesswire.com

    Get the next $MGRM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MGRM

    DatePrice TargetRatingAnalyst
    12/9/2024$4.00Buy
    ROTH MKM
    More analyst ratings

    $MGRM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Monogram Technologies Inc.

      10-Q - Monogram Technologies Inc. (0001769759) (Filer)

      5/14/25 3:59:51 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Monogram Technologies Inc. (0001769759) (Filer)

      4/29/25 6:05:28 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Monogram Technologies Inc.

      S-8 - Monogram Technologies Inc. (0001769759) (Filer)

      4/17/25 3:12:04 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monogram Technologies Reports First Quarter 2025 Financial Results

      Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

      5/14/25 4:01:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA

      Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data RequestManagement Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TEXAS / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application").The Application was submitted on

      12/18/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million

      AUSTIN, TEXAS / ACCESSWIRE / December 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open market by certain related parties including Chief Financial Officer Noel Knape, totaling approximately $1 million. Additional details can be found on the Form 8-K filed today by the Company under Item 8.01 Other Events."Our senior management team has purchased shares in the open market, reflecting high confidence in our strategy and expectation to create long-term shareholder value," said Ben Sexson

      12/2/24 4:05:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Monogram Accepted to NVIDIA Inception Program

      Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co

      4/11/24 1:20:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Knape Noel was granted 288,461 shares (SEC Form 4)

      4 - Monogram Technologies Inc. (0001769759) (Issuer)

      11/26/24 8:52:37 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Knape Noel

      4 - MONOGRAM ORTHOPAEDICS INC (0001769759) (Issuer)

      4/26/24 3:28:17 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Monogram Technologies with a new price target

      ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

      12/9/24 7:59:36 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Financials

    Live finance-specific insights

    See more
    • Monogram Technologies Reports First Quarter 2025 Financial Results

      Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

      5/14/25 4:01:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

      AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can b

      11/12/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Announces Preferred Stock Dividends

      AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024. Holders of record will receive the dividend

      10/1/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care